✦ LIBER ✦

Phase II Trial of Antiepidermal Growth Factor Receptor Antibody C225 in Patients with Advanced Renal Cell Carcinoma

✍ Scribed by Robert J. Motzer; Robert Amato; Mary Todd; Wen-J Poo Hwu; Roger Cohen; Jose Baselga; Hyman Muss; Michael Cooper; Richard Yu; Michelle S. Ginsberg; Michael Needle

Book ID: 110428936
Publisher: Springer US
Year: 2003
Tongue: English
Weight: 45 KB
Volume: 21
Category: Article
ISSN: 0167-6997
DOI: 10.1023/a:1022928612511

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cutaneous side-effects in cancer patient

Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225

✍ K.J. Busam; P. Capodieci; R. Motzer; T. Kiehn; D. Phelan; A.C. Halpern 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 752 KB

Phase II trial of topotecan in patients

Phase II trial of topotecan in patients with advanced renal cell carcinoma

✍ Teresa Murray Law; David H. Ilson; Robert J. Motzer 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 159 KB

Phase II trial of Didemnin B in patients

Phase II trial of Didemnin B in patients with advanced renal cell carcinoma

✍ Robert Motzer; Howard Scher; Dean Bajorin; Cora Sternberg; George J. Bosl 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 115 KB

Twenty-three patients with advanced renal cell cancer were treated with Didemnin B. One partial response was achieved (5070) in 21 evaluable patients. An allergic reaction was noted in four patients including one patient with anaphylaxis. Didemnin B is not recommended in the treatment of renal cell

Phase II trial of liposomal encapsulated

Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma

✍ Teresa Murray Law; Peter Mencel; Robert J. Motzer 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 158 KB

Phase II Trial of Irofulven (6-Hydroxyme

Phase II Trial of Irofulven (6-Hydroxymethylacylfulvene) for Patients with Advanced Renal Cell Carcinoma

✍ William J. Berg; Lawrence Schwartz; Richard Yu; Madhu Mazumdar; Robert J. Motzer 📂 Article 📅 2001 🏛 Springer US 🌐 English ⚖ 53 KB

Clinical trial with escalating doses of

Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx

✍ Henning Bier; Thomas Hoffmann; Ulrich Hauser; Michael Wink; Martin Öchler; Andre 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 99 KB